A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,400estimated
Sites
77
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2016-10-29 | actual | When the study began enrolling |
| Primary completion | 2021-01-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-28 | estimated | The whole study's end, after follow-up |
| First posted | 2016-11-01 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alzheimer Disease
- Mild Cognitive Impairment
Intervention
- Drug: Florbetapir F 18 PET Scan — also filed as LY3078786
Primary outcome
what the primary-completion date above is the date OFMean Economic Cost Associated with Amyloid Positive AD
measured Baseline through Study Completion (36 Months)
Publications
- PMID 31561360 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed